← Leaderboards
Andrew M Evens
Northwestern University
$3,800,221
Attributed
$6,819,135
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $827.1K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,819,135 · 8
By mechanism
R01$4,319,283 · 2
R33$1,174,545 · 1
K23$657,275 · 1
M01$262,343 · 2
T32$253,203 · 1
R03$152,486 · 1
Top collaborators
- Ronald B Gartenhaus5 shared
- Susan Kenyon Parsons4 shared
- Brian C-H Chiu3 shared
- Tony Jun Huang3 shared
- Tania Tali Konry3 shared
Most similar at Northwestern University
Same institution · by research overlap
- Amy Beth Heimberger$11,078,637
- Alison K Criss$15,016,124
- Athanassios Argiris$721,909
Others in their field
Top investigators on “S Lymphoma”
- David Heimbrook · Leidos Biomedical Research, Inc.$171,980,034
- Richard L Schilsky · University Of Chicago$120,036,663
- Joseph Sparano · Montefiore Medical Center (Bronx, Ny)$113,682,224
- Ronald T Mitsuyasu · University Of California Los Angeles$103,553,444
- Monica M Bertagnolli · Strang Cancer Prevention Center$61,393,123
- Charles A Coltman · Southwest Oncology Group$55,198,633
Research focus
S LymphomaMalignant NeoplasmsInnovationRelapseResponseDoseLymphomaClinical TrialsTumorNovel TherapeuticsCessation Of LifeCollaborationsBaseImageResistanceChemotherapyNon-Hodgkin&AposPathway InteractionsCellsProgression-Free SurvivalsBiologyMolecularClinical ResearchHodgkin Disease
Grant awards (25)
Modeling Multi-Source Data in Hodgkin Lymphoma$666,718
R01 · FY2025 · CA
Modeling Multi-Source Data in Hodgkin Lymphoma$633,900
R01 · FY2024 · CA
Modeling Multi-Source Data in Hodgkin Lymphoma$808,155
R01 · FY2023 · CA
Modeling Multi-Source Data in Hodgkin Lymphoma$827,059
R01 · FY2022 · CA
Determining treatment sensitivity in B cell lymphoma by novel microfluidics-based NK cell immunogenicity platform$379,335
R33 · FY2020 · CA
Determining treatment sensitivity in B cell lymphoma by novel microfluidics-based NK cell immunogenicity platform$373,709
R33 · FY2019 · CA
Determining treatment sensitivity in B cell lymphoma by novel microfluidics-based NK cell immunogenicity platform$421,501
R33 · FY2018 · CA
MAP Kinase Signaling in Lymphoma: A Novel Therapeutic Paradigm$345,726
R01 · FY2015 · CA · contact PI
MAP Kinase Signaling in Lymphoma: A Novel Therapeutic Paradigm$335,991
R01 · FY2014 · CA · contact PI
MAP Kinase Signaling in Lymphoma: A Novel Therapeutic Paradigm$311,368
R01 · FY2013 · CA · contact PI
Research Training in Oncology$253,203
T32 · FY2013 · CA · contact PI
MAP Kinase Signaling in Lymphoma: A Novel Therapeutic Paradigm$16,858
R01 · FY2013 · CA · contact PI
MAP Kinase Signaling in Lymphoma: A Novel Therapeutic Paradigm$373,508
R01 · FY2012 · CA · contact PI
Impact of Lifestyle with Tumor Pathways and Microenvironment on Lymphoma Survival$44,975
R03 · FY2010 · CA · contact PI
Impact of Lifestyle with Tumor Pathways and Microenvironment on Lymphoma Survival$32,189
R03 · FY2010 · CA · contact PI
Targeting the Mitochondria to Treat Lymphoma and Myeloma$131,445
K23 · FY2009 · CA · contact PI
Impact of Lifestyle with Tumor Pathways and Microenvironment on Lymphoma Survival$75,322
R03 · FY2009 · CA · contact PI
Targeting the Mitochondria to Treat Lymphoma and Myeloma$131,450
K23 · FY2008 · CA · contact PI
Targeting the Mitochondria to Treat Lymphoma and Myeloma$131,455
K23 · FY2007 · CA · contact PI
NU 02H8: A PHASE I TRIAL OF REDOX REGULATION IN PATIENTS WITH RELAPSED NHL$125,211
M01 · FY2007 · RR · contact PI
Targeting the Mitochondria to Treat Lymphoma and Myeloma$131,460
K23 · FY2006 · CA · contact PI
NU 02H8: A PHASE I TRIAL OF REDOX REGULATION IN PATIENTS WITH RELAPSED NHL$101,365
M01 · FY2006 · RR · contact PI
Targeting the Mitochondria to Treat Lymphoma and Myeloma$131,465
K23 · FY2005 · CA
NU 02H8: A PHASE I TRIAL OF REDOX REGULATION IN PATIENTS WITH RELAPSED NHL$22,103
M01 · FY2005 · RR
NU 02H8: A Phase I Trial of Redox Regulation in Patients with Relapsed NHL$13,664
M01 · FY2004 · RR